Five shikonin derivatives containing deoxyshikonin exhibit in vitro and in vivo anticancer effects by inducing murine melanoma B16F10 cells apoptosis and arrest in the sub‐G1 phase through repression of Bcl‐2 proteins and activation of Bax expression.21 Here, BCL2 is linked to melanoma.